Cord blood-derived hematopoietic stem/progenitor cells

Current challenges in engraftment, infection, and ex vivo expansion

Katsuhiro Kita, Jong Lee, Celeste Finnerty, David Herndon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation.

Original languageEnglish (US)
Article number276193
JournalStem Cells International
DOIs
StatePublished - 2011

Fingerprint

Hematopoietic Stem Cells
Fetal Blood
Infection
Transplantation
Unrelated Donors
Cell Separation
Hematologic Neoplasms
Blood Donors
Bone Marrow Transplantation
Cause of Death
Morbidity
Recurrence
Mortality

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

@article{c7fff374f14a44239a2d2d44cc425420,
title = "Cord blood-derived hematopoietic stem/progenitor cells: Current challenges in engraftment, infection, and ex vivo expansion",
abstract = "Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation.",
author = "Katsuhiro Kita and Jong Lee and Celeste Finnerty and David Herndon",
year = "2011",
doi = "10.4061/2011/276193",
language = "English (US)",
journal = "Stem Cells International",
issn = "1687-9678",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Cord blood-derived hematopoietic stem/progenitor cells

T2 - Current challenges in engraftment, infection, and ex vivo expansion

AU - Kita, Katsuhiro

AU - Lee, Jong

AU - Finnerty, Celeste

AU - Herndon, David

PY - 2011

Y1 - 2011

N2 - Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation.

AB - Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation.

UR - http://www.scopus.com/inward/record.url?scp=79959248613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959248613&partnerID=8YFLogxK

U2 - 10.4061/2011/276193

DO - 10.4061/2011/276193

M3 - Article

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-9678

M1 - 276193

ER -